AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest

AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest
Aravive's experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients taking part in a Phase 1b/2 trial show. The company will increase enrollment in this U.S. study to further evaluate these early outcomes. “We have decided to expand the clinical trial to validate that early positive efficacy signal,” Laura Bonifacio PhD, vice president of Aravive, said in a press release. “If we continue to see a robust efficacy signal, we plan to work with FDA to explore the most efficient regulatory pathway to bring this drug to the patients in need.” AVB-500 (previously known as AVB-S6-500) binds with high affinity to a protein called growth arrest-specific factor 6 (GAS6), preventing it from interacting with the AXL receptor and inhibiting the activation of the Gas6-AXL pathway, which plays a role in cancer progression. High levels of GAS6 in the blood are associated with more aggressive cancer, resistance to treatment, and poorer outcomes in people with ovarian and breast cancer, and in those with 
Subscribe or to access all post and page content.